Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 6
2006 9
2007 9
2008 11
2009 15
2010 15
2011 11
2012 21
2013 48
2014 37
2015 29
2016 38
2017 40
2018 35
2019 12
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

281 results
Results by year
Filters applied: . Clear all
Page 1
Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R, et al. Curr Clin Pharmacol 2016 - Review. PMID 27086601
Despite some mishaps in clinical trials related to drugs acting on endocannabinoid system, still lot of research is being carried out to explore and establish the therapeutic targets for both cannabinoid receptor agonists and antagonists. ...Another angle to be introspected for therapeutic abilities of this group of drugs is non-CB1 and non-CB2 receptor targets for cannabinoids. ...
Despite some mishaps in clinical trials related to drugs acting on endocannabinoid system, still lot of research is being carried out to exp …
Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.
Lötsch J, et al. Eur J Pain 2018 - Review. PMID 29160600
This is reflected in antinociceptive effects of cannabinoids in preclinical models of inflammatory, cancer and neuropathic pain, and by nociceptive hypersensitivity of cannabinoid receptor-deficient mice. ...Thus, while preclinical evidence supports cannabinoid-based analgesics, human evidence presently provides only reluctant support for a broad clinical use of cannabinoid-based medications in pain therapy. ...
This is reflected in antinociceptive effects of cannabinoids in preclinical models of inflammatory, cancer and neuropathic pain, and …
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.
Pacher P, et al. Nat Rev Cardiol 2018 - Review. PMID 28905873
The past decade has seen a nearly tenfold increase in the THC content of marijuana as well as the increased availability of highly potent synthetic cannabinoids for recreational use. ...In this Review, we summarize the role of the endocannabinoid system in cardiovascular disease, and critically discuss the cardiovascular consequences of marijuana and synthetic cannabinoid use. ...
The past decade has seen a nearly tenfold increase in the THC content of marijuana as well as the increased availability of highly potent sy …
Translational potential of allosteric modulators targeting the cannabinoid CB(1) receptor.
Lu D, et al. Acta Pharmacol Sin 2019 - Review. PMID 30333554 Free PMC article.
The cannabinoid type-1 (CB(1)) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due to its involvement in many physiological processes. ...In this paper, we review and summarize the complex pharmacological profiles of each class of CB(1) allosteric modulators, the development of new classes of CB(1) allosteric modulators and the results from in vivo assessments of their therapeutic value....
The cannabinoid type-1 (CB(1)) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due t …
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Pertwee RG. Philos Trans R Soc Lond B Biol Sci 2012 - Review. PMID 23108552 Free PMC article.
This review mentions several possible additional therapeutic targets for cannabinoid receptor agonists. These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders. ...These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB(2) receptors, and/or (v) adjunctive 'multi-targeting'....
This review mentions several possible additional therapeutic targets for cannabinoid receptor agonists. These include o …
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Hasenoehrl C, et al. Expert Rev Gastroenterol Hepatol 2017 - Review. PMID 28276820 Free PMC article.
Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are already available with a narcotic prescription. ...Expert commentary: Cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD patients, leaving medical professionals without evidence and guidelines....
Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are …
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.
Hill MN, et al. Neuropsychopharmacology 2018 - Review. PMID 28745306 Free PMC article.
In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, there has been a surge of public and research interest in the role of cannabinoids in the regulation of stress-related biological processes and in their potential therapeutic application for stress-related psychopathology. Here we review the current state of knowledge regarding the effects of cannabis and cannabinoids in PTSD and the preclinical and clinical literature on the effects of cannabinoids and endogenous cannabinoid signaling systems in the regulation of biological processes related to the pathogenesis of PTSD. ...
In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, there has been …
Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids.
O'Brien M and McDougall JJ. Curr Opin Pharmacol 2018 - Review. PMID 29635215
While the majority of these reports are anecdotal, there is a growing body of scientific evidence which supports the analgesic potential of cannabinoids to treat OA pain. ...This review summarizes the components of the ECS and details the latest research pertaining to plant-based and man-made cannabinoids for the treatment of OA pain. ...
While the majority of these reports are anecdotal, there is a growing body of scientific evidence which supports the analgesic potential of …
Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
Maccarrone M, et al. Expert Rev Clin Pharmacol 2017 - Review. PMID 28276775
Modulation of the activities of the eCB system can be therapeutic in a number of diseases. Research into the eCB system has been paralleled by the development of agents that interact with cannabinoid receptors. ...Expert commentary: From the different therapeutic possibilities, THC/CBD oromucosal spray has been in clinical use for approximately five years in numerous countries world-wide for the management of multiple sclerosis (MS)-related moderate to severe resistant spasticity. ...
Modulation of the activities of the eCB system can be therapeutic in a number of diseases. Research into the eCB system has been para …
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.
Hasenoehrl C, et al. Neurogastroenterol Motil 2016 - Review. PMID 27561826 Free PMC article.
Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety of herbal and synthetic cannabinoid (CB) compounds to study the endocannabinoid system (ECS), a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors. ...In addition, other receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), the peroxisome proliferator-activated receptor alpha (PPARα) and the G-protein coupled receptor 55 (GPR55), are important participants in the actions of CBs in the gut and critically determine the course of bowel inflammation and colon cancer. ...
Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety of herbal and synt …
281 results
Jump to page
Feedback